Study of IDE849 for Patients with DLL3 Expressing Tumors, Including Small Cell Lung Cancer

Inclusion Criteria

• Willing to participate and able to sign a consent form.
• Diagnosed with small cell lung cancer that has returned or progressed after standard treatments, including platinum-based therapy and certain immunotherapies, unless unsuitable for immunotherapy.
• No more than two previous chemotherapy treatments and no more than three total treatments for recurrent or metastatic cancer.
• Willing to provide blood or tumor samples for testing.
• Have at least one tumor that can be measured by scans.
• In good general health with a performance status score of 0 or 1.
• Expected to live more than 3 months.
• Have adequate bone marrow and organ function.
• Women of childbearing age must agree to use effective birth control.

Exclusion Criteria

• Have a mix of small cell and non-small cell lung cancer, except for certain types.
• Have untreated or active brain tumors.
• Have severe heart or blood vessel disease.
• Have had significant bleeding in the last 3 months.
• Have lung diseases affecting breathing or a history of lung inflammation from previous treatments.
• Have had severe infections in the last 4 weeks.
• Have a history of immune system deficiency or positive HIV test.
• Have known or suspected hepatitis infection.
• Have had active tuberculosis in the last year.
• Have received certain cancer treatments recently.
• Have taken certain medications that affect drug processing in the body recently.
• Have had previous treatment with DLL3 ADC or certain other cancer drugs.
• Have had recent high-dose radiation therapy.
• Have had major surgery or significant injury in the last 4 weeks.
• Women who are pregnant, breastfeeding, or planning to become pregnant during the study and for 8 months after the last dose.